Cullinan Therapeutics Stock Falls Despite Positive Phase 3 Lung Cancer Data

Cullinan Therapeutics (NASDAQ:CGEM) shares dropped 6.3% on Monday despite the company and its partners announcing that a Phase 3 trial for their lung cancer therapy, zipalertinib, met its primary endpoint. The market's reaction suggests investors are looking past the headline efficacy data to focus on the drug combination's safety profile and still-maturing survival data.

Trial Meets Primary Efficacy Goal

The REZILIENT3 trial evaluated zipalertinib plus chemotherapy in 279 patients with a specific form of non-small cell lung cancer (NSCLC) who had not received prior treatment for advanced disease. According to results presented at the World Conference on Lung Cancer, the study successfully met its primary goal of improving progression-free survival (PFS).

Key efficacy results included:

• Progression-Free Survival: Patients receiving the zipalertinib combination achieved a median PFS of 14.5 months, a significant improvement over the 8.5 months seen in the chemotherapy-alone arm.
• Risk Reduction: The hazard ratio for disease progression or death was 0.50, indicating a 50% reduction in risk for patients on the combination therapy.
• Response Rate: The objective response rate was 65.0% for the zipalertinib arm, compared to 40.3% for chemotherapy alone.

Investor Focus on Safety and Survival Data

Ad

Despite the strong efficacy, the market's negative response may be tied to the trial's safety and overall survival data. Grade 3 or higher adverse events occurred in 87.1% of patients receiving the combination therapy, substantially higher than the 54.4% in the chemotherapy-only group. The company noted these were primarily manageable hematologic events.

Furthermore, the overall survival data remains immature. An interim analysis showed a hazard ratio for death of 0.72, which trends positive but is not yet conclusive. Investors may be waiting for more mature data to confirm a definitive survival benefit before fully valuing the drug's commercial potential.

Context and Next Steps

Cullinan is developing zipalertinib in partnership with Taiho Oncology and Taiho Pharmaceutical. The therapy targets NSCLC with EGFR exon 20 insertion mutations, a challenging-to-treat patient population. Following the positive results, the companies stated they plan to discuss the data with health authorities to work toward making zipalertinib available to patients.